HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Beaute, Inc.

This article was originally published in The Rose Sheet

Executive Summary

Pierre Berlancourt is named president and CEO of the New York City-based company. He will retain his duties as director of resources for Paris-based Sanofi Beaute, S.A. and will be based in Paris. Berlancourt came to Sanofi Beaute in 199 when the firm acquired Yves Saint Laurent Parfums; he was with YSL for four years. Prior to serving with YSL, he spent 22 years in manufacturing at P&G. Berlancourt succeeds Lawrence Aiken, who had held the post since 1989. Previously, he was U.S. president and chief operating officer at Parfums Givenchy. Aiken commented that he decided to resign from Sanofi "some time ago," but wanted to stay through the September launch of Champagne in the U.S. He added that he plans to continue working in the beauty industry. Donald Loftus will remain Sanofi Beaute, Inc. exec VP and chief operation officer, reporting to Berlancourt
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS000918

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel